SCHEMBL20079998

SCHEMBL20079998

OCc1csnc1-c1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.45
NOTUM Q6P988 5/20 0.40
CYP11B1 P15538 2/20 0.37
CYP11B2 P19099 2/20 0.37
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
AKR1B1 P15121 1/20 0.35
PTGDR2 Q9Y5Y4 4/20 0.35
KDM4E B2RXH2 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GFER P55789 1/20 0.34
NR4A2 P43354 1/20 0.34
HTT P42858 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23655493 0.82 CYP11B1 (0.44) FFAR4NOTUMCYP11B1CYP11B2AKR1B1
SCHEMBL31526173 0.81 CYP11B1 (0.53) NOTUMCYP11B1CYP11B2AKR1B1KDM4E
SCHEMBL23655506 0.77 FFAR4 (0.45) FFAR4CYP11B1CYP11B2ADORA3ADORA2A
SCHEMBL16048520 0.72 FFAR4 (0.49) FFAR4CYP11B1CYP11B2PTGDR2
SCHEMBL28358537 0.72 FFAR4 (0.44) FFAR4CYP11B1CYP11B2PTGDR2
SCHEMBL27751435 0.72 FFAR4 (0.40) FFAR4ADORA3ADORA2AADORA2BADORA1
SCHEMBL2344081 0.70 ALAD (0.44) FFAR4PTGDR2KDM4EALDH1A1CYP1A2
SCHEMBL4049174 0.69 TRPV1 (0.47) NOTUMKDM4ELMNAGAAL3MBTL1
SCHEMBL10628766 0.69 NOTUM (0.45) NOTUMPTGDR2KDM4ELMNAGAA
SCHEMBL2928527 0.68 NOTUM (0.51) FFAR4NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10618893-B2 GPR120 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICALS NV (BE) 2020-04-14 US disclosed
US-20190071435-A1 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2019-03-07 US disclosed
EP-3114123-B1 ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071435-A1 GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES GPR119, GLP1R, GCGR FFAR4 54/4885NOTUM 4817/4885CYP11B1 603/4885
US-10618893-B2 GPR120 agonists for the treatment of type II diabetes GPR119, GLP1R, GCGR FFAR4 54/4885NOTUM 4817/4885CYP11B1 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.